What about the Rodney Dangerfield stock 'MRNA'?
IT HAS A NEW CEO, MORE IN VIVO NEWS THAN ELVIS SANG VIVA LAS VEGAS ON STAGE, HIGH TARGET PRICES BY RESEARCHERS, AND
DEDICATED, ADDICTED SHAREHOLDERS WHO LOOK AT THE STOCK IS IF IT WERE ONE OF THEIR CHILDREN AND CAN NOT DO ANY WRONG.
NOT A STRONG STOCK, WITH HEAVY WALL STREET BACKING, NO SERIOUS EARNINGS REVENUES, AND THE STOCK NEVER MAKES ANY IMPORTANT LIST ON ANY INVESTMENT SITE.
SOME BIOTECH'S HAVE COME BACK STRONGLY,
BUT THIS ONE HAS HIGH EXPENSES, LIMITED MONEY FOR EXPENSES, AND SO EARLY IN THEIR PRE-CLINICAL STAGES.
REALLY WITH MARKET CONDITIONS, YEAR END APPROACHING, UNSTABLE ECONOMY, IT HAS NO OTHER DIRECTION BUT DOWNWARD.
READ THE 'MRNA' MESSAGE BOARD, THERE IS NO INTELLECT THERE, JUST A QUICK BUCK MENTALITY VS NUMBERS.
SHAREHOLDERS HAVE BEEN THE BEST PIPELINE FOR 'MRNA' AND WHEN IT WAS NASTECH, SINCE 26 YEARS AGO.
WHERE IS IT AT TODAY, NOWHERE!
OCTOBER 16TH $1.34
BUY OR SAY BYE BYE!
